Quantcast

Elsevier and NextBio Sign Partnership to Enrich ScienceDirect Content, Accelerating Life Sciences, Health Sciences and Chemistry Research

June 12, 2009

AMSTERDAM, June 12 /PRNewswire/ –

– Improving Research Discoverability and Productivity

Elsevier today announced a new partnership agreement with NextBio,
provider of an innovative platform that enables life science researchers to
search, discover, and share knowledge locked within public and proprietary
data to enrich ScienceDirect content. This agreement allows for an
integration of NextBio’s unique set of ontology-based semantic tools and a
compilation of high quality sources of public data on ScienceDirect,
providing health science, life science and chemistry researchers with a
dynamic platform to improve discoverability and research productivity.

While most scientific information on genes, pathways, diseases, tissues
and compounds is available online, it currently resides in various,
disconnected, locations. Enhancing ScienceDirect with NextBio’s biomedical
ontology framework enables life sciences, health sciences and chemistry
researchers to analyze ScienceDirect content and search ScienceDirect
peer-reviewed literature together with publicly available research data from
PubMed, clinical trials, experimental data, and news articles, on one single
platform. The new enhancement will become available on ScienceDirect and
accessible to subscribed users in summer 2009.

“ScienceDirect plays a crucial role in researchers’ workflow.” explained

Rafael Sidi, Vice President, Product Management, ScienceDirect. “We
continuously seek new ways to help accelerate science by increasing research
productivity and efficiency. Partnering with NextBio will help further this
mission by allowing us to provide intelligent and insightful information and
smarter content to help researchers do research better.

Researchers at Stanford Genome Technology Center use ScienceDirect to
enhance and accelerate their life sciences research efforts,” said Dr. Baback
Gharizadeh
, Research Scientist at Stanford University. “We are excited about
ScienceDirect leveraging NextBio’s technology to explore literature findings
within the context of public experimental data and related basic and clinical
research. Its unique content and the ability to test new hypotheses provide
the next logical step in exploiting published studies.”

“We are excited to be working with the world’s largest science,
technology and medical publisher,” said Saeid Akhtari, Co-founder, President
and Chief Executive Officer, of NextBio. “Combining the depth of our search
and discovery capabilities, and our unique content with the breath of the
ScienceDirect platform will create new opportunities for Life Sciences,
Health Sciences and Chemistry researchers to quickly gain access to the most
current and comprehensive insight in their field.”

About NextBio

NextBio is the provider of an innovative platform that enables life
science researchers to search, discover, and share knowledge locked within
public and proprietary data. NextBio’s platform seamlessly combines powerful
tools with unique correlated content to transform information into knowledge,
providing the foundation for new scientific discoveries. NextBio helps
organizations increase productivity and dramatically improve collaboration
across therapeutic groups and geographic boundaries. NextBio is delivered as
a SaaS (Software as a Service) solution resulting in quick deployment and
rapid return on investment.

Today, NextBio is used by over a million researchers at the world’s top
commercial and academic institutions. NextBio’s enterprise solution has been
deployed at Burnham Institute for Medical Research, Celgene, Eli Lilly,
Genzyme, Johnson & Johnson, Merck, Regeneron, Scripps Research Institute,
Stanford University, and Takeda, among many others. To learn more about
NextBio, please visit http://www.nextbio.com.

About ScienceDirect

Over a quarter of the world’s full text scientific, technical and medical
(STM) peer-reviewed articles – managed by renowned editors, written by
respected authors and read by researchers from around the globe – are
available in one place: ScienceDirect.

Elsevier’s extensive and unique full-text collection covers authoritative
titles from the core scientific literature including high impact factor
titles such as THE LANCET, Cell and Tetrahedron. Over nine million articles
are available online, including Articles in Press which offer online access
to recently accepted manuscripts. The critical mass of trusted information
available on ScienceDirect is unsurpassed. Coverage includes over 2,500
journals published by Elsevier and dynamic linking to journals from
approximately 2,000 STM publishers through CrossRef. An expanding program of
online major reference works, handbooks, book series and over 4,400 eBooks in
all fields of science seamlessly interlinks with primary research referenced
in journal articles.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and
medical information products and services. Working in partnership with the
global science and health communities, Elsevier’s 7,000 employees in over 70
offices worldwide publish more than 2,000 journals and 1,900 new books per
year, in addition to offering a suite of innovative electronic products, such
as ScienceDirect (http://www.sciencedirect.com/), MD Consult (
http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/),
bibliographic databases, and online reference works.

Elsevier (http://www.elsevier.com/) is a global business headquartered in
Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of
Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading
publisher and information provider. Operating in the science and medical,
legal, education and business-to-business sectors, Reed Elsevier provides
high-quality and flexible information solutions to users, with increasing
emphasis on the Internet as a means of delivery. Reed Elsevier’s ticker
symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and
ENL (New York Stock Exchange).

    For more information, see http://www.elsevier.com

    Contact:
    Malkie Bernheim/Jessica Disch
    Padilla Speer Beardsley
    +1-212-752-8338
    mbernheim@psbpr.com/jdisch@psbpr.com

SOURCE Elsevier and ScienceDirect


Source: newswire



comments powered by Disqus